Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models (2023)
- Authors:
- USP affiliated authors: LOTUFO, LETICIA VERAS COSTA - ICB ; PARISE FILHO, ROBERTO - FCF ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; CARLOS, JORGE ANTONIO ELIAS GODOY - ICB ; ALMEIDA, LARISSA COSTA DE - ICB ; WAITMAN, KAROLINE DE BARROS - FCF
- Unidades: ICB; FCF
- Assunto: LEUCEMIA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher: Sociedade Brasileira de Química/SBQ
- Publisher place: São Paulo
- Date published: 2023
- Source:
- Título do periódico: Anais
- Conference titles: Reunião Anual da Sociedade Brasileira de Química/RASBQ
-
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models. 2023, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2023. Disponível em: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf. Acesso em: 27 abr. 2024. -
APA
Carlos, J. A. E. G., Almeida, L. C. de, Lima, K., Tavares, M. T., Waitman, K. de B., Lotufo, L. V. C., et al. (2023). Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf -
NLM
Carlos JAEG, Almeida LC de, Lima K, Tavares MT, Waitman K de B, Lotufo LVC, Parise Filho R, Machado Neto JA. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models [Internet]. Anais. 2023 ;[citado 2024 abr. 27 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf -
Vancouver
Carlos JAEG, Almeida LC de, Lima K, Tavares MT, Waitman K de B, Lotufo LVC, Parise Filho R, Machado Neto JA. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models [Internet]. Anais. 2023 ;[citado 2024 abr. 27 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf - Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models
- Design of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy
- HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents
- DNA damaging agents and DNA repair: from carcinogenesis to cancer therapy
- A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells
- ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells
- New kinase and HDAC hybrid inhibitors: recent advances and perspectives
- Novel [6]-gingerol triazole derivatives and their antiproliferative potential against tumor cells
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
